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ABSTRACT 
Objective.   Relative to SLE, epidemiologic studies on chronic cutaneous lupus 
erythematosus (CCLE) are rare and limited to populations without racial diversity. We sought 
to provide minimum estimates of the incidence of primary CCLE (CCLE in absence of SLE) 
in a predominantly white and black population in the Southestern United States. 
Methods. The Georgia Lupus Registry used multiple sources for case finding, including 
dermatology and rheumatology practices, multispecialty healthcare facilities, and 
dermatopathology reports. Cases with a clinical or clinical-histological diagnosis of CCLE 
were classified as definite. Cases ascertained exclusively from dermatopathology reports were 
categorized as probable. Age-standardized incidence rates stratified by sex and race were 
calculated for discoid lupus erythematosus (DLE) in particular and for CCLE in general.  
Results. The overall age-adjusted estimates for combined (definite and probable) CCLE were 
3.9/100,000 person-years (95% CI: 3.4,4.5). The overall age-adjusted incidence of definite 
and combined DLE were 2.9 (95% CI: 2.4,3.4) and 3.7 (95% CI: 3.2,4.3)  per 100,000 person-
years, respectively. With capture-recapture methods, the age-adjusted incidence of definite 
DLE increased to 4.0  (95% CI: 3.2,4.3). Black-to-white and female-to-male incidence ratios 
were 5.4 and 3.1 for definite DLE.  
Conclusion. Our findings underscore striking racial disparities in the susceptibility for 
primary CCLE, with black people experiencing between three and five-fold increased 
incidence of CCLE in general and DLE in particular, compared to white people. Gender 
differences were consistent with those reported previously, with a three times higher risk of 
DLE in females compared to males. 
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Significance and Innovations 
 
- There are no studies that directly compare racial differences of the incidence of 
CCLE in a single population.  
-  The incidence of CCLE in general and DLE in particular in a large and 
predominantly black/white population of the Southeastern US was found to be 
between three and five-fold increased in black compared to white people. 
- The GLR black/white disparities in the incidence of CCLE are analogous to those 
described for SLE in the same geographic area,  suggesting that these two extremes of 
the lupus spectrum may share common biological and environmental pathways that 
contribute to the higher risk in black individuals.  
- Whether black populations are also disproportionally stricken by more severe CCLE 
phenotypes and poorer outcomes, as it has been described in SLE, and whether black 
individuals with CCLE are at higher risk of progression from cutaneous to systemic 
lupus phenotypes, are questions that warrant further research. 	
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Cutaneous lupus erythematosus (CLE) comprises multiple dermatological disorders, which can 
be limited to the skin or associated with underlying systemic lupus erythematosus (SLE). CLE 
exhibits distinctive clinical and histopathological features, which are categorized as acute 
(ACLE), subacute (SCLE) or chronic (CCLE)1, 2. CCLE comprises discoid lupus erythematosus 
(DLE), lupus erythematosus profundus (LEP), lupus erythematous tumidus (LET) and chilblain 
lupus erythematosus (CHLE). CCLE subtypes are less likely to overlap with or progress to SLE 
than other CLE types2, 3, 4; however, they pose significant burden to individuals and the 
healthcare system. For instance, DLE, the hallmark of CCLE, represents 80% of the CLE 
conditions seen by dermatologists5-7. Characterized by erythematous indurated plaques with 
adherent scale that heals with atrophic scarring and dyspigmentation8, and largely found on the 
scalp, face and ears, DLE can cause scarring alopecia and facial disfigurement2, 5, 6, 9, with 
substantial impact on individuals’ quality of life10, 11.  
 
DLE has a relatively characteristic clinical-pathological description and has been 
recognized in individuals of all races 12-15. Although DLE is less likely associated with SLE2 than 
other CLE subtypes, only a few population-based studies have estimated the incidence of DLE in 
absence of SLE (or “primary” DLE)4, 15-17.  Early reports suggest that similar to SLE, DLE might 
be more frequent among blacks, compared to whites18. However, recent incidence estimates were 
higher (3.6/100,000/year) in a predominantly white population of the United States than in the 
African-descendant population of French Guiana South America (nearly 2.6/100,000/year)16, 17. 
Methodological differences limit the comparability of both studies, and to our knowledge, no 
epidemiological studies have targeted black/white populations to assess racial disparities in the 
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susceptibility of CCLE. We sought to determine minimum estimates for the incidence of CCLE 
in general and DLE in particular, in a black/white population of the Southeastern United States.  
 
PATIENTS AND METHODS 
Georgia Lupus Registry (GLR) data were examined to assess CCLE and DLE in absence 
of SLE.  The GLR is a population-based registry designed to better estimate the incidence and 
prevalence of SLE in a large population with high proportion of high-risk individuals of black 
race. The GLR methodology has been described extensively19, 20. Briefly, GLR is one of five 
lupus registries funded by the Centers for Disease Control and Prevention21 to conduct more 
reliable surveillance of lupus in the US. The GLR catchment area , Fulton and DeKalb counties 
in Atlanta, encompassed a population of 1.5 million inhabitants with nearly even representation 
of whites and blacks. The Georgia Department of Public Health (GA DPH) allowed Emory 
University to collect private health information (PHI) and review medical records without patient 
consent using the health surveillance exemption to the the Health Insurance Portability and 
Accountability Act (HIPAA) privacy rules (45 CFR parts 160 and 164), a key authorization to 
ascertain and validate cases on a population level. The project was approved by the Institutional 
Review Boards of Emory University and the GA DPH. 
 
Study population and period: 
The study population consisted of all residents of Fulton and DeKalb counties, the central 
counties in the Atlanta metropolitan area. The Bureau of the Census population estimates in 2002 
for the two counties was 1,552,970 with 51.1% women, 49.3% blacks, and 46.4% whites21. 
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Incidence rates for a diagnosis from January 1st 2002 through December 31st 2004 were 
estimated on a catchment area population of 4,742,264 person-years.  
 
Ascertainment and validation of CCLE and DLE 
Although the GLR was primarily designed to ascertain the full spectrum of SLE, registry 
efforts also entailed finding and validating individuals with a variety of lupus-related conditions, 
including primary CCLE20. GLR used multiple sources in the pluralistic US health care system 
to find potential cases. The primary sources included hospitals, rheumatology, nephrology and 
dermatology practices in and around the catchment area. As described elsewhere, 18 of 25 
dermatology groups in the target area contributed, along with the other sources, to finding CCLE 
cases20. With the exception of one high yield practice, dermatology groups that declined to 
contribute to the registry efforts were either cosmetically oriented practices or self-reported to be 
very low yield for CCLE. Administrative databases were queried for the International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic code 
695.4 (discoid lupus), in addition to 710.0 (SLE), 710.8 (other specified connective tissue 
disease), and 710.9 (unspecified connective tissue disease).  
Secondary sources for CCLE cases included the two largest dermatopathology 
laboratories in the target area, which were queried for the ICD-9 code 695.4 or for a wide range 
of key words in skin pathology reports (e.g. CLE, lupus, discoid, DLE, LE, tumidus, chilblain, 
panniculitis, lupus profundus).  
After screening for residence in the catchment counties during the target period, medical 
records and pathology reports were requested for an extended period (e.g. 2001-2005), allowing 
for more complete capture of clinical information. Capturing PHI was required to avoid counting 
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the same case multiple times. All available medical records for each case were fully abstracted 
for over 200 data elements, 36 of which corresponded to cutaneous manifestations (see 
Supplemental Data Dictionary Index). Abstractors also recorded the final diagnosis stated by the 
attending physician, type of physician (dermatologist, rheumatologist, nephrologist, other), the 
earliest date of diagnosis (CCLE, SLE), the ACR criteria for SLE, and earliest date of occurrence 
of each ACR criterion and skin manifestation. Demographic information, including race, was 
gathered from medical records. Detailed definitions for each data element were stated in a data 
dictionary. Abstractors were thoroughly trained and tested before entering the field, where they 
continued to undergo periodic quality assessments.  
 
Case Definitions 
The accepted diagnosis of CCLE is a characteristic clinical presentation with supporting 
histological features2, 8. This standard may not be achieved in every case, as biopsy may be 
unnecessary, particularly when lesions are classic in appearance or present on cosmetically 
sensitive areas.  In these cases, diagnosis is based solely on clinical evaluation. Therefore, the 
requirement of histological confirmation for case definition in epidemiological studies may lead 
to underestimation of the population burden of CCLE . 
Following the classification by Gilliam and Sontheimer22, we included as CCLE any of 
the following: DLE, lupus panniculitis, lupus profundus, lupus tumidus or chilblain lupus, or a 
combination of any of those conditions. Definitions of CCLE subtypes and keywords used to 
guide medical data abstraction are depicted as Suplemental Table 1. In order to estimate the 
incidence of primary CCLE, we excluded cases that either had a diagnosis of SLE by the treating 
dermatologist, rheumatologist, and/or nephrologist, or fulfilled the American College of 
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Rheumatology (ACR) classification criteria for SLE23 within two months of the initial CCLE 
diagnosis. Two months was chosen as an appropriate timeframe to conduct clinical evaluation 
for possible systemic manifestations that may have occurred associated to the onset of CCLE.  
 CCLE cases were classified as DLE or other CCLE subtypes, and subdivided into either 
definite or probable categories. Definite CCLE were cases with a clinical-pathological or clinical 
diagnosis of a specific CCLE subtype documented in the medical records. Probable CCLE were 
cases ascertained through a dermatopathology report, in which both the presumed clinical 
diagnosis by the attending dermatologists and the histopathology findings were highly suggestive 
of either DLE, LEP or LET, but the original medical records from the attending dermatologist 
who ordered the biopsy were unavailable. Cases were pre-classified as probable DLE if they 
were either (i) submitted by the attending dermatologist to rule out DLE and had a histological 
description consistent with CLE, or (ii) submitted to rule out CLE, lupus, or a similar condition 
and had a histological description consistent with a discoid pattern of CLE (interface dermatitis 
at the dermal-epidermal junction, superficial and deep dermal perivascular and periadnexal 
lymphocytic infiltrate, +/- increased dermal mucin, and follicular hyperkeratosis)24. Similarly, 
cases with both a clinical assessment of probable CLE and a histological description suggestive 
of lupus erythematosus panniculitis (lobular lymphocytic panniculitis, paraseptal lymphoid 
follicles, hyaline degeneration of the fat, mucin deposition, +/- overlying features of DLE) or 
lupus erythematosus tumidus (interstitial mucin deposition, superficial and deep dermal 
lymphocytic perivascular and periadnexal infiltrate, with relative sparing of the dermal-
epidermal junction) were pre-classified as probable LEP or LET, respectively24, 25. Next, two 
study dermatologists with extensive experience in CLE (SP, LDA) reviewed the 
dermatopathology reports for final case validation. 
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 Incidence estimates were reported for three case definition categories: (i) definite DLE; 
(ii) “combined” definite and probable DLE; and (iii) “combined” definite and probable CCLE, 
which included definite and probable cases of all CCLE subtypes.  
 
Statistical Analysis:  
Crude incidence rates and 95% confidence intervals (CI) as well as race- and sex-
stratified incidence were estimated using methods based on the Poisson distribution26. The 
numerator consisted of cases with a first diagnosis in 2002-2004. Denominator data for DeKalb 
and Fulton counties were obtained from the post-censal population estimates for the years 2002-
200427. Age-adjusted estimates and 95% CI were calculated using the standard 2000 projected 
age distribution by direct standardization, which calculates age standardized rates and “exact” CI 
based on the gamma distribution28.  To estimate underascertainment of definite DLE cases, we 
conducted capture–recapture analysis accounting for the degree of overlap among multiple case-
finding sources29. Community dermatologists, community rheumatologists & other specialists,  
and multispecialty healthcare facilities (e.g. community hospitals, Emory University Health 
System, Grady Health System, Kaiser Permanente) were chosen to be the primary sources of 
cases. Log-linear modeling was performed to estimate the number of persons with definite DLE 
who were missed in the population. The best fitting model was determined by goodness of fit 
statistics and the parsimony principle. Capture-recapture methods were implemented using SAS 
Proc Genmod. 
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RESULTS 
Of 231 cases with a new diagnosis of CCLE between 2002 and 2004, 41 (17.5%) were 
excluded because they fulfilled ≥4 ACR criteria for SLE and the remaining 190 were primary 
CCLE. Among them, 147 with either a clinical-pathological or a clinical diagnosis of CCLE 
were classified as definite CCLE, and 43 that were ascertained through a pathology report were 
classified as probable CCLE (Figure 1). The overlap of individuals ascertained by sources are 
depicted in Figure 2.  
 
Description of CCLE subtypes 
     DLE. There were 139 cases with definite DLE, of which 88 (63.3 %) had a clinical-
pathological diagnosis of DLE by a dermatologist (Figure 1). Among the remaining 51, a clinical 
diagnosis of DLE was stated by a dermatologist in 30 (21.6%), a rheumatologist in 10 (7.2%), 
and other physicians in 11 (7.9%) cases. Among 43 probable CCLE, 39 were classified as  DLE 
(Figure 1), of which 32 (78.6%) had a clinical diagnosis of DLE by a dermatologist and a 
histological description consistent with DLE (n=31) or CLE (n=1)24. Among the 7 remaining, 5 
had a clinical diagnosis of CLE. The histopathological description was consistent with the 
discoid pattern of CLE as described in the Methods, in all those 7 cases. Overall, 178 cases had 
Combined DLE (definite or probable).  
 
     Other CCLE subtypes. There were 8 cases with definite CCLE different than DLE: 4 had LEP 
(1 with a consistent skin biopsy), 3  LET (1 with a consistent biopsy) and 1 had a clinical-
pathological diagnosis of LEP and LEP. Four cases ascertained through dermatopathology 
reports were classified as probable CCLE (1 with LEP and 3 with LET). The biopsies of these 
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four cases were requested to rule out CLE, and the histological description and pathologist 
assessment were consistent with LEP and LET, as described in the Methods.  
 
Incidence of DLE  
Crude and age-adjusted incidence rates of DLE were similar, overall and across 
demographic categories. The age-adjusted incidence rate was 2.9 (95% CI: 2.4,3.4) per 100,000 
person-years for definite DLE and 3.7 (95% CI: 3.2,4.3) per 100,000 person-years for combined 
(definite and probable) DLE (Table 1). The highest age-adjusted incidence rates of definite and 
combined DLE were for black females (definite DLE: 6.6 [95% CI: 5.3,8.2] per 100,000 person-
years; combined DLE: 7.9 [95% CI: 6.5,9.6] per 100,000 person-years). The female:male ratio 
was 3.1 for definite DLE and 2.8 for combined DLE. Incidence was also higher in blacks, with 
black:white ratios of 5.4 for definite DLE, and 4.1 for combined DLE. The lowest incident rates 
for all categories were in white males (0.2 [95% CI: 0.1,0.7] and 0.7 [95% CI: 0.4,1.4] per 
100,000 person-years, for definite and combined DLE, respectively). Data on race were not 
available in 7 individuals, who were not included in the estimates by race.  
Using capture-recapture methods, 53 additional definite DLE cases were ascertained, 
rendering the age-adjusted incidence for definite DLE to 4.0 (95% CI: 3.5,4.7) (Table 2).  There 
were 35 and 6 definite DLE cases missed for blacks and whites, respectively. Capture-recapture 
analyses yielded incidence estimates per 100,000 person-years of 6.4 (95% CI: 5.4,7.5) and 1.2 
(95% CI: 0.8,1.7) for blacks and whites, respectively, with a black:white ratio of 5.3. 
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Incidence of CCLE   
Crude and age-adjusted incidence rates for all CCLE subtypes, including cases with 
definite and probable CCLE were 4.0 (95% CI: 3.5,4.6) and 3.9 (95% CI: 3.4,4.5) per 100,000 
person-years, respectively. Crude and age-adjusted rates were similar across demographic 
categories. The highest age-adjusted incidence rates were for black females (8.3 [95% CI: 
6.8,10] per 100,000 person-years) and the lowest for white males (0.9 [95% CI: 0.5,1.6] per 
100,000 person-years). The female:male and the black:white ratios were 2.5 and 3.9, 
respectively.  
Blacks developed CCLE nearly 4 years earlier on average compared to whites (p= 0.11).  
The mean age at onset for CCLE and DLE are depicted in Table 34. 
Age-specific incidence rates of combined DLE were significantly higher for black 
individuals aged 30-59, compare to their white counterparts (Figure 3). While the incidence peak 
for blacks was 13.7/100,000 at age 40-49, whites showed two peaks of 3.2 and 2.9 /100,000 
person-years at 40-49 and >60, respectively. Moreover, age-specific incidence rates reached 
10.3/100,000 person-years at age 40-49 in black females, as opposed to 2.6 and 2.5 /100,000 
person-years, at age 40-49  and >60, respectively in white females (data not shown).  The 
incidence of DLE peaked at ages 40-49 and 50-59 (3.4 and 3.6/100,000 person-years, 
respectively) in black males, in contrast to approximately 0.5/100,000 persons-year in white 
males for all age groups older than 20 (data not shown). 
Progression to SLE:  9 and 16 cases progressed to SLE at 1 and 3 years since diagnosis, 
respectively. The progression rate was 5.3% (95% CI 2.8-10.0) and 12.3% (95% CI 7.5-20.1) at 
1 and 3 years, respectively.  
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DISCUSSION 
This study leveraged the population-based Georgia Lupus Registry (GLR) to report 
minimum incidence estimates of CCLE in a predominantly black/white population in the 
Southeastern US. Overall incidence rates of definite DLE, combined DLE (definite and 
probable), and combined CCLE (all CCLE disorders, including definite and probable) were 2.9, 
3.7, and 3.9 per 100,000 person-years, respectively. Using capture-recapture analysis, the 
number of new definite DLE cases increased from 139 to 192, rendering an age-adjusted 
incidence of 4.0 per 100,000 person-years.  
 
 Substantial racial disparities in the susceptibility for CCLE in general, and DLE in 
particular, were uncovered. The black:white ratios were 3.4, 3.9, and 5.4 for combined CCLE, 
combined DLE, and definite DLE, respectively. Interestingly, the black:white ratios of primary 
CCLE reported in this study are similar to that for SLE reported by our group in the same 
geographic area20.   
 
Prior population-based studies of the incidence were conducted in two predominantly 
Caucasian populations of the US (Olmsted County, Minnessotta) and Sweden, as well as in an 
African-descendant population in French Guiana, South America4, 16, 17. DLE annual incidence of 
1.4 per 100,000 for white individuals in our catchment area is lower than previous estimates in 
Sweden (3.2/100,000) and Olmsted County, US (3.6/100,000)4, 16. Operational differences may 
account for our lower estimates in whites. For instance, the DLE definition in the Swedish study 
was based on ICD-10 codes, which could lead to overestimated incidence4. In contrast, nearly 
80% of DLE cases in our study were validated through medical records review. Moreover, 
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because we targeted CCLE without co-existing SLE, we excluded cases that fulfilled the ACR 
criteria for the classification of SLE around the diagnosis of DLE. Such approach differs from 
the Swedish study, in which 24% of DLE cases had co-existing SLE4. The US study, in contrast, 
used data from the Rochester Epidemiology Project, which can more efficiently retrieve medical 
information from multiple sources for Olmsted County residents16. Moreover, Olmsted residents 
face lower healthcare access barriers than people in the US Southern states. Consequently, we 
cannot exclude underascertainment associated to undiagnosis as a potential explanation of the 
lower incidence among whites in our study. Additionally, variability in biological (e.g. DNA 
methylation) and environmental (e.g. sun exposure, early diagnosis/treatment) factors between 
populations and geographic areas can account for differences in DLE estimates30.  
 
Notably, the incidence of  CCLE in the Atlanta black population was 6.2, as opposed to 
2.6 in French Guiana, where 90% of the population are African-descendent17. However, 
methodological differences limit the comparability of both studies, and whether socio-
environmental factors play a role in the higher risk of CCLE in blacks from the Southeast US 
deserve further research.  
 
Our findings suggest that black/white disparities may also occur in relation to the age at 
diagnosis, with blacks tending to develop CCLE at earlier ages compared to whites, as noted 
with SLE in the same population20. Incident rates for combined DLE in black individuals aged 
30-59 were significantly higher than in their white counterparts. However, the difference in mean 
age at DLE diagnosis by race (43.6 and 47.5 years for blacks and whites, respectively) was not 
statistically significant, which can be potentially explained by the small number of whites in our 
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registry. The mean age at DLE diagnosis was 48.5 and 53 years-old in the predominantly 
Caucasian populations of Olmstead County and Sweden, respectively4, 16, and 32 years-old in the 
African-descendent population of French Guiana17. These findings support racial differences in 
the natural history of primary CCLE, analogous to SLE.  
 
The overall incidence rates of CCLE in general, and DLE in particular, are relatively 
lower than the rates that we recently reported for SLE in the same catchment area20. While the 
GLR overall age-adjusted incidence rate for SLE was 5.6/100,000 person-years, rates of DLE 
and CCLE were 3.7 and 3.9/100,000, respectively. Our findings differ from those from the 
largely white Olmsted County population, where the incidence of  CLE and SLE were similar15 . 
However, in addition to CCLE, the Rochester study targeted bullous and SCLE, conditions 
linked to the HLA-B8, DR3 haplotype, which in turn disproportionately strike Caucasian 
individuals31.  
 
Other factors can potentially explain the relatively lower incidence of primary CCLE 
compared to SLE in the GLR catchment area. First, socio-environmental factors might increase 
the risk of co-existing SLE and CCLE or progression from primarily cutaneous to systemic 
phenotypes30.  GLR data support a higher rate of progression from primary CCLE to SLE in our 
area compared to Olmsted county16, 32. While the 5-year cumulative incidence of SLE among 
primary CLE in Olmsted County was 5%31, we reported 5% and 12% SLE progression at 1 and 3 
years. Additionally, 15% of incident SLE patients ascertained in our catchment area had co-
existing DLE, as opposed to only 7% in Olmsted Country16, 20. Secondly, disproportionaltely 
greater underascertainment may have occurred for CCLE/DLE than SLE in our study. Although 
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the majority of collaborating dermatologists were medical, cosmetic practices were not included 
as sources of case finding, potentially leading to missed cases. Underascertainment may have 
also occurred because dermatology offices were contacted for case finding between 4-6 years 
after the surveillance dates of interest.  This time discrepancy may have resulted in 
underreporting CCLE cases due to limited accessibility of records. To overcome this limitation, 
we conducted capture-recapture analysis. This method rendered an overall age-adjusted 
incidence for definite DLE of 4.0 per 100,000 person-years. The number of cases  missed were 
estimated to be 35 and 6 among black and white people, respectively, raising the incidence of 
definite DLE from 4.0 to 6.5 and from 0.9 to 1.2 for blacks and whites, respectively. The 
black:white ratio after adjustment remained over 5, stressing out the greater predisposition for 
this condition in blacks. Additionally, because GLR data were collected from medical records, 
we can not exclude that some cases with overlapping CCLE and SLE may have been 
misclassified as primary CCLE. However, data abstraction entailed periodic audits to ensure 
consistency and accuracy in abstracting ACR criteria and other clinical data.  Additionally, 
almost all rheumatology practices in the catchment area served as sources of cases, and all 
available medical records for each incident case were fully abstracted. As a result, the number of 
underreported incident SLE cases rendered by capture-recapture methods was very low (n=31), 
suggesting that the majority of overlapping SLE/CCLE cases were captured by GLR methods20. 
Second, because our case definition relied on medical records review and we assumed that 
attending physicians knew how to differentiate CCLE/DLE from other major forms of CLE and 
other autoimmune conditions, we cannot exclude misclassification of CCLE cases. However, 
these are limitations of population-based studies in general, where individual study physician 
assessment is not feasible13, 15-17, 33. Third, while a clinical or clinical-histological documentation 
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of the diagnosis of CCLE was obtained in nearly 80% of our cases, medical records were 
unavailable for 43 individuals who were further classified and analyzed separately as probable 
CCLE based on data from dermatopathology reports.  Fourth, patients with SCLE were not 
included because only 8 cases with a dermatologist-confirmed diagnosis of primary SCLE were 
ascertained. Fifth, it is possible that DLE may have been underdiagnosed by physicians among 
whites, a diagnostic challenge faced by many clinicians. Additionally, we cannot exclude 
underascertainment of whites with CCLE due to lower participation of dermatology practices 
located in areas with higher concentration of whites. Sixth, the results of this study are best 
generalized to white and black individuals in the Southeastern US. Because race was assigned 
based primarily on the physician’s assessment documented in the medical record, it may not 
reflect the patient’s true self-identity, particularly among multiracial individuals. 
 
Our study has several strengths. First, this is the first report of the incidence of primary 
CCLE and its DLE subtype in a large black/white population from the same geographic area. 
With the exception of the study in French Guiana17, prior epidemiologic studies have focused on 
overall CLE and targeted primarily Caucasian populations. Furthermore, the GLR allowed for 
acquisition of clinical data (including earliest date of each ACR criteria) from medical records 
across multiple facilities, reducing misclassification of incident SLE case as primary CCLE and 
vice versa. Moreover, most facilities provided medical records for an extended period (e.g. 2001-
2005) and all available medical charts from multiple sources were fully abstracted. Thus, our 
efforts entailed the collection of comprehensive clinical information since the disease onset 
throughout 12/31/2004, potentially reducing lost to followup. The GLR also cross-referenced 
records from multiple sources, avoiding double-counting of cases. 
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In conclusion, this is the first epidemiologic description of primary CCLE in a 
predominantly black/white population and finds that CCLE disproportionately affects black 
individuals, paralleling the disparities observed in SLE in this region20 and other US 
populations30, 34.  
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Table 1. Incidence Rates of DLE and CCLE in Fulton/DeKalb, Georgia (01/01/2002-12/31/2004) 
  
Definite DLE Combined (definite and probable) 
DLE 
Combined (definite and probable) 
CCLE 
Race/Sex 
Catchment 
Population 
(person-years) 
N 
Cases 
Crude Rate 
(95% CI) 
Age-adjusted 
Rate 
(95% CI) 
N 
Cases 
Crude Rate 
(95% CI) 
Age-adjusted 
Rate 
(95% CI) # Cases 
Crude Rate 
(95% CI) 
Age-adjusted 
Rate 
(95% CI) 
Overall 4742264 139 2.9 (2.5,3.5) 2.9 (2.4,3.4) 178 3.8 (3.2,4.3) 3.7 (3.2,4.3) 190 4.0 (3.5,4.6) 3.9 (3.4,4.5) 
Female 2424592 105 4.3 (3.6,5.2) 4.3 (3.5,5.2) 131 5.4 (4.6,6.4) 5.3 (4.5,6.3) 137 5.7 (4.8,6.7) 5.6 (4.7,6.6) 
Male 2317672 34 1.5 (1.0,2.0) 1.4 (1.0,2.0) 47 2.0 (1.5,2.7) 1.9 (1.4,2.6) 53 2.3 (1.7,3) 2.2 (1.7,2.9) 
Black 2321302 113 4.9 (4.0,5.9) 4.9 (4.1,5.9) 135 5.8 (4.9,6.9) 5.8 (4.9,6.9) 143 6.2 (5.2,7.3) 6.2 (5.3,7.3) 
Black Female 1239819 83 6.7 (5.4,8.3) 6.6 (5.3,8.2) 100 8.1 (6.6,9.8) 7.9 (6.5,9.6) 104 8.4 (6.9,10.2) 8.3 (6.8,10) 
Black Male 1081483 30 2.8 (1.9,4.0) 2.8 (1.9,4.0) 35 3.2 (2.3,4.5) 3.3 (2.4,4.5) 39 3.6 (2.6,4.9) 3.7 (2.7,5) 
White 2210389 20 0.9 (0.6,1.4) 0.9 (0.6,1.4) 33 1.5 (1.1,2.1) 1.4 (1,2) 37 1.7 (1.2,2.3) 1.6 (1.2,2.3) 
White Female 1082131 17 1.6 (1.0,2.5) 1.6 (1,2.5.0) 24 2.2 (1.5,3.3) 2.2 (1.5,3.3) 26 2.4 (1.6,3.5) 2.4 (1.6,3.5) 
White Male 1128258 3 0.3 (0.1,0.8) 0.2 (0.1,0.7) 9 0.8 (0.4,1.5) 0.7 (0.4,1.4) 11 1.0 (0.5,1.7) 0.9 (0.5,1.6) 
Rates are per 100,000 person-years (95% confidence intervals [95%CI]). Age-adjusted rates used the 2000 projected US population. The 
definite definition for discoid lupus erythematosus (DLE) consisted of cases with a clinical or clinical-pathological diagnosis of DLE. The 
combined definition for DLE included cases validated as definite and those ascertained through pathology reports (probable). Combined 
chronic cutaneous lupus (CCLE) included either definite or probable cases with all types of CCLE, including DLE. Three cases of Asian 
race and 7 of unknown race were not included in the estimates by race 
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Table 2. Incidence Rates of DLE in Fulton/DeKalb, Georgia (01/01/2002-12/31/2004)  
Adjusted by Capture-recapture Methods 
   Capture-recapture* 
Race 
Catchment 
Area Population 
(person-years) 
No. of 
Cases 
Crude Rate 
(95% CI) 
Age-adjusted Rate 
(95% CI) 
No. of Cases 
Missed 
(95% CI) 
Capture–recapture 
Adjusted Rate 
(95% CI) 
Total 4742264 139 2.9 (2.5,3.5) 2.9 (2.4,3.4) 53 (23,119) 4.0 (3.5,4.7) 
Black 2321302 113 4.9 (4,5.9) 4.9 (4.1,5.9) 35 (12,100) 6.4 (5.4,7.5) 
White 2210389 20 0.9 (0.6,1.4) 0.9 (0.6,1.4) 6 (1,36) 1.2 (0.8,1.7) 
* Values are the estimated number of definite DLE cases that were missed and the capture–recapture–adjusted 
incidence rate 
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Table 3. Age at diagnosis in incident DLE and CCLE by Black and White Race 
Case Definition Descriptor Black White P value 
Combined DLE Count (N) 135 33  
 Mean ± SD 43.6 ± 13.1 47.5 ± 14.2 0.13 
 Median (IQR) 43.6 (36.0-51.1) 44.3 (37.7-60.5)  
 Range (9.4-83.5) (20.5-76.5)  
Combined CCLE Count (N) 143 37  
 Mean ± SD 43.9 ± 13.2 47.2 ± 14.9 0.19 
 Median (IQR) 43.6 (36.0-52.3) 44.3 (37.7-60.5)  
 Range (9.4-83.5) (15.9-76.5)  
  Abbreviations: DLE, discoid lupus erythematosus; CCLE, chronic cutaneous lupus erythematosus 
